Literature DB >> 24845157

CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function.

Tanya Girard1, Denis Gaucher2, Mohamed El-Far2, Gaëlle Breton2, Rafick-Pierre Sékaly3.   

Abstract

CD86 and CD80, the ligands for the co-stimulatory molecules CD28 and CTLA-4, are members of the Ig superfamily. Their structure includes Ig variable-like (IgV) domains, Ig constant-like (IgC) domains and intracellular domains. Although crystallographic studies have clearly identified the IgV domain to be responsible for receptor interactions, earlier studies suggested that both Ig domains are required for full co-signaling function. Herein, we have used deletion and chimeric human CD80 and CD86 molecules in co-stimulation assays to study the impact of the multimeric state of IgV and IgC domains on receptor binding properties and on co-stimulatory function in a peptide-specific T cell activation model. We report for the first time the presence of CD80 dimers and CD86 monomers in living cells. Moreover, we show that the IgC domain of both molecules inhibits multimer formation and greatly affects binding to the co-receptors CD28 and CTLA-4. Finally, both IgC and intracellular domains are required for full co-signaling function. These findings reveal the distinct but complementary roles of CD80 and CD86 IgV and IgC domains in T cell activation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD80; CD86; CTLA-4; Immunoglobulin; T cells

Mesh:

Substances:

Year:  2014        PMID: 24845157     DOI: 10.1016/j.imlet.2014.05.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

Review 1.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

2.  Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways.

Authors:  Geffen Kleinstern; Huihuang Yan; Michelle A T Hildebrandt; Joseph Vijai; Sonja I Berndt; Hervé Ghesquières; James McKay; Sophia S Wang; Alexandra Nieters; Yuanqing Ye; Alain Monnereau; Angela R Brooks-Wilson; Qing Lan; Mads Melbye; Rebecca D Jackson; Lauren R Teras; Mark P Purdue; Claire M Vajdic; Roel C H Vermeulen; Graham G Giles; Pier Luigi Cocco; Brenda M Birmann; Peter Kraft; Demetrius Albanes; Anne Zeleniuch-Jacquotte; Simon Crouch; Yawei Zhang; Vivekananda Sarangi; Yan Asmann; Kenneth Offit; Gilles Salles; Xifeng Wu; Karin E Smedby; Christine F Skibola; Susan L Slager; Nathaniel Rothman; Stephen J Chanock; James R Cerhan
Journal:  Hum Mol Genet       Date:  2020-01-01       Impact factor: 6.150

Review 3.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 4.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies.

Authors:  Taweewun Hunsawong; Sineewanlaya Wichit; Thipwipha Phonpakobsin; Yongyuth Poolpanichupatam; Chonticha Klungthong; Napaporn Latthiwongsakorn; Butsaya Thaisomboonsuk; Rawiwan Im-Erbsin; In-Kyu Yoon; Damon W Ellison; Louis R Macareo; Anon Srikiatkhachorn; Robert V Gibbons; Stefan Fernandez
Journal:  Heliyon       Date:  2017-03-21

6.  Attogram-level light-induced antigen-antibody binding confined in microflow.

Authors:  Takuya Iida; Shiho Tokonami; Shota Hamatani; Yumiko Takagi; Kana Fujiwara; Mamoru Tamura
Journal:  Commun Biol       Date:  2022-10-06

Review 7.  Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.

Authors:  Megan M Y Hong; Saman Maleki Vareki
Journal:  Cancers (Basel)       Date:  2022-03-20       Impact factor: 6.639

8.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.

Authors:  Yunlong Zhao; Calvin K Lee; Chia-Hao Lin; Rodrigo B Gassen; Xiaozheng Xu; Zhe Huang; Changchun Xiao; Cristina Bonorino; Li-Fan Lu; Jack D Bui; Enfu Hui
Journal:  Immunity       Date:  2019-11-19       Impact factor: 31.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.